The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...